PT  - JOURNAL ARTICLE
AU  - Bifulco, Maurizio
AU  - Grimaldi, Claudia
AU  - Gazzerro, Patrizia
AU  - Pisanti, Simona
AU  - Santoro, Antonietta
TI  - Rimonabant: Just an Antiobesity Drug? Current Evidence on Its Pleiotropic Effects
AID  - 10.1124/mol.106.033118
DP  - 2007 Jun 01
TA  - Molecular Pharmacology
PG  - 1445--1456
VI  - 71
IP  - 6
4099  - http://molpharm.aspetjournals.org/content/71/6/1445.short
4100  - http://molpharm.aspetjournals.org/content/71/6/1445.full
SO  - Mol Pharmacol2007 Jun 01; 71
AB  - The advent of the highly selective cannabinoid receptor (CB1) antagonist, rimonabant (SR141716; Acomplia) can revolutionize the ability of the clinicians to manage obesity. Large-scale clinical trials have demonstrated that rimonabant therapy can reduce obesity. Although, the precise mechanisms of action of rimonabant have to be further dissected, it is emerging, from both preclinical and clinical research, that not only is rimonabant an antiobesity drug, but also its pleiotropic functions affect a broad range of diseases, from obesity-related comorbidities to drug dependence and cancer. Here we review recent data from the literature and discuss the full pharmacological potential of this drug. The American Society for Pharmacology and Experimental Therapeutics